We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Thermo Fisher (TMO) Introduces Vanquish Neo UHPLC System
Read MoreHide Full Article
Thermo Fisher Scientific Inc. (TMO - Free Report) recently announced the introduction of the new Thermo Scientific Vanquish Neo UHPLC System and Thermo Scientific PepMap Neo Columns, which help users overcome limitations of the existing low-flow LC instruments. The system is intended for high sensitivity LC-mass spectrometry (LC-MS) applications, technical capabilities and easy integration with Thermo Scientific PepMap Neo Columns and Thermo Scientific mass-spectrometry portfolio.
The recent development will enhance Thermo Fisher’s high performance chromatography solutions.
More on the News
The new Thermo Scientific Vanquish Neo UHPLC System and Thermo Scientific PepMap Neo Columns provide application flexibility and robust analytical performance at flow rates from 1 nL/min -100 µL/min. This can go up to 1500 bar. Novice and expert LC-MS users will enjoy high productivity, minimized method overhead time, and long-term operation essential for 24/7 large sample cohort analysis.
The all-in-one nano- capillary- and micro-flow liquid chromatography (LC) system will benefit principal investigators, laboratories, and proteomics researchers in academia, biopharma and contract research organizations.
Image Source: Zacks Investment Research
The new system provides seamless integration with the comprehensive portfolio of Thermo Scientific mass spectrometers and will enhance quantitation through high-injection volume linearity, precision and accuracy.
Significance of the Launch
Per Thermo Fisher’s management, the Vanquish Neo UHPLC System and PepMap Neo Columns will enable long-term operation with maximum performance levels without compromise.
The Vanquish Neo UHPLC System will change the conventional way of performing proteomics studies by offering the long-term robustness and flow-range versatility required for deep and quick LC-MS profiling of thousands of proteomes together with PepMap Columns and high-resolution accurate mass (HRAM) systems.
Industry Prospects
Per a report by MARKETANDMARKETS, the global chromatography instruments market is expected to rise from $8.6 billion in 2020 to $11.0 billion by 2025, at a CAGR of 5.1%. Growing investments in the pharmaceutical R&D and rising food safety concerns worldwide are the factors driving the market.
Recent Developments
In September 2021, Thermo Fisher announced that lab managers, technology leaders and principal scientists in pharmaceutical, food and environmental laboratories can now benefit from the Thermo Scientific TSQ Plus triple quadrupole mass spectrometer (MS) portfolio, which increases workflow throughput through superior data acquisition and polarity switching speeds.
In the same month, Thermo Fisher and AstraZeneca (AZN - Free Report) collaborated under a multiyear global agreement to co-develop next-generation sequencing based companion diagnostics (CDx). Through the agreement, the companies aim to grow AstraZeneca’s portfolio of targeted therapies.
Price Performance
Shares of the company have gained 36.4% in a year’s time compared with the industry’s rise of 19.5%.
Zacks Rank and Key Picks
Currently, Thermo Fisher carries a Zacks Rank #3 (Hold).
Image: Bigstock
Thermo Fisher (TMO) Introduces Vanquish Neo UHPLC System
Thermo Fisher Scientific Inc. (TMO - Free Report) recently announced the introduction of the new Thermo Scientific Vanquish Neo UHPLC System and Thermo Scientific PepMap Neo Columns, which help users overcome limitations of the existing low-flow LC instruments. The system is intended for high sensitivity LC-mass spectrometry (LC-MS) applications, technical capabilities and easy integration with Thermo Scientific PepMap Neo Columns and Thermo Scientific mass-spectrometry portfolio.
The recent development will enhance Thermo Fisher’s high performance chromatography solutions.
More on the News
The new Thermo Scientific Vanquish Neo UHPLC System and Thermo Scientific PepMap Neo Columns provide application flexibility and robust analytical performance at flow rates from 1 nL/min -100 µL/min. This can go up to 1500 bar. Novice and expert LC-MS users will enjoy high productivity, minimized method overhead time, and long-term operation essential for 24/7 large sample cohort analysis.
The all-in-one nano- capillary- and micro-flow liquid chromatography (LC) system will benefit principal investigators, laboratories, and proteomics researchers in academia, biopharma and contract research organizations.
The new system provides seamless integration with the comprehensive portfolio of Thermo Scientific mass spectrometers and will enhance quantitation through high-injection volume linearity, precision and accuracy.
Significance of the Launch
Per Thermo Fisher’s management, the Vanquish Neo UHPLC System and PepMap Neo Columns will enable long-term operation with maximum performance levels without compromise.
The Vanquish Neo UHPLC System will change the conventional way of performing proteomics studies by offering the long-term robustness and flow-range versatility required for deep and quick LC-MS profiling of thousands of proteomes together with PepMap Columns and high-resolution accurate mass (HRAM) systems.
Industry Prospects
Per a report by MARKETANDMARKETS, the global chromatography instruments market is expected to rise from $8.6 billion in 2020 to $11.0 billion by 2025, at a CAGR of 5.1%. Growing investments in the pharmaceutical R&D and rising food safety concerns worldwide are the factors driving the market.
Recent Developments
In September 2021, Thermo Fisher announced that lab managers, technology leaders and principal scientists in pharmaceutical, food and environmental laboratories can now benefit from the Thermo Scientific TSQ Plus triple quadrupole mass spectrometer (MS) portfolio, which increases workflow throughput through superior data acquisition and polarity switching speeds.
In the same month, Thermo Fisher and AstraZeneca (AZN - Free Report) collaborated under a multiyear global agreement to co-develop next-generation sequencing based companion diagnostics (CDx). Through the agreement, the companies aim to grow AstraZeneca’s portfolio of targeted therapies.
Price Performance
Shares of the company have gained 36.4% in a year’s time compared with the industry’s rise of 19.5%.
Zacks Rank and Key Picks
Currently, Thermo Fisher carries a Zacks Rank #3 (Hold).
A couple of better-ranked stocks from the broader medical space are Envista Holdings Corporation (NVST - Free Report) and BellRing Brands, Inc. (BRBR - Free Report) , each carrying a Zacks Rank #2 (Buy). You can see the complete list of Zacks #1 Rank (Strong Buy) stocks here.
Envista Holdings has an estimated long-term earnings growth rate of 27%.
BellRing Brands has an estimated long-term earnings growth rate of 29%.